Stifel raised the firm’s price target on Ideaya Biosciences to $68 from $63 and keeps a Buy rating on the shares. The firm, which thinks adding IDE397 should improve efficacy of AMG 193, is “bullish” that combo data can beat expectations, which it thinks are set by monotherapy results, the analyst tells investors in a preview of the combination data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target lowered to $58 from $60 at Citi
- Ideaya Biosciences removed from Analyst Focus List at JPMorgan
- Ideaya Biosciences price target lowered to $66 from $69 at JPMorgan
- Ideaya Biosciences price target lowered to $53 from $60 at Oppenheimer
- Ideaya Biosciences reports Q2 EPS (68c), consensus (53c)